Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced the filing of a new provisional patent application covering new chemical entities (NCEs) that expand the company's next-generation DMT and 5-MeO-DMT, or 'Family 4', platform, currently under development.
The company said the new patent application exemplifies its corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who are waiting for transformative medicines and covers novel chemical space while maintaining the functionality of traditional psychedelics.
"As we get more human clinical data from first-generation psychedelic drugs, we will unravel how different patients respond to different psychedelic therapies,” the company’s CEO James Lanthier said in a statement. “Our expectation is that different patients will respond to different treatments and paradigms. In an effort to build a toolbox that helps the most patients, Mindset continues to build out its patent portfolio.
READ: Mindset Pharma CEO James Lanthier says company pursuing development partners to support clinical process
Mindset noted that it has a broad IP footprint in the psychedelic space with novel chemical entities in development that mimic the functionality of first-generation psychedelic medicines and have optimized pharmacological and safety profiles to address diverse in-clinic needs. The company uses a differentiated battery of highly specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing toward human clinical trials.
“The Mindset 'Family 4' compounds have shown promise in efficacy and safety at a range of doses compared to first-generation DMT and 5-MeO-DMT compounds based on rodent pre-clinical models,” Lanthier continued. Our strong IP position on this family enhances their commercial viability. We are working hard to bring these innovative mental health solutions to the clinic as fast as possible to waiting patients with our collaborators at the McQuade Center for Strategic Research and Development (MSRD).”
Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
Contact the author at stephen.gunnion@proactiveinvestors.com